Celldex Therapeutics falls on stopping development of drug for esophageal condition

Celldex Therapeutics

19/08/2025 21:26

** Shares of drug developer Celldex Therapeutics CLDX.O fall 15% to $20.42 after the bell

** Co says will not advance the development of its experimental drug, barzolvolimab, in eosinophilic esophagitis - a chronic inflammatory disease of the esophagus

** In a mid-stage study, the drug met the main goal and showed it could potently deplete mast cells in the gastrointestinal tract, but did not result in improvement in symptoms compared to placebo

** Co will continue studying barzolvolimab for other skin conditions

** Stock down ~5% YTD

 (Reporting by Sriparna Roy in Bengaluru)

 ((Sriparna.Roy@thomsonreuters.com;))